follow-up of today's conversation
1 messages over —, 2020-03-18 – 2020-03-18.
-
Folks: When we put together the proposal for the protocols/distribution of Hydroxychloroquine (HC) and Remdesivir, I feel that it is important that we do not make the program the same for each. We need to link Remdesivir to a much more strict protocol as opposed to HC which is an approved drug and although it has some adverse events, we have tons of experience with it. I am comfortable with the HC plan as discussed in the Oval. In contrast, we know much less about the unapproved drug Remdesivir. I have more concern about the potential toxicities of this unapproved, investigational drug in the context of COVID-19 as well as the need to prove that it works before we widely distribute it. The bulk of the data that we have with Remdesivir is in Ebola where it did not have a clear benefit. We should consider leading with HC in a flexible distribution protocol and . Ttaly >31,000 accelerating the clinical trial aspect of Remdesivir. Also, we clearly need to have a discussion with Gilead about drug supply and the plan for any accelerated study. Finally, and importantly, the Chinese already have a clinical trial of Remdesivir with more than 200 people enrolled in the advanced disease arm of the study. Someone should directly contact the Chinese investigators (Bin Cao, et al) and find out if they have any preliminary data on efficacy and safety. In my mind it is imperative that we find out what they know before we launch any distribution program. Happy to discuss. Thanks, Tony Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (301) 496-2263 FAX: (301) 496-4409 E-mail: afauci@niaid.nih.gov PRESS: Dave Webb Radio Show; Mike Gallagher Show; FOX Tucker Carlson; CNN Cuomo Prime Time;